RTN4 Antibody

1. This review aims at presenting our current knowledge on the role of Nogo-A in the visual system and to discuss how its therapeutic targeting may promote visual improvement in ophthalmic diseases. PMID:28408340
2. CAA and TATC Insertion/Deletion Genetic Polymorphisms of RTN4 3'-UTR are associated with Hepatocellular Carcinoma PMID:28144881
3. Nogo-B was shown to play an important negative role in apoptotic signaling through its interaction with c-FLIP in colorectal cancer cells. PMID:29684585
4. NOGO-B/RTN4B and NOGO-A/RTN4A are simultaneously expressed in cultured epithelial, fibroblast and neuronal cells. Morphological analysis of cells with manipulated levels of NOGO-B/RTN4B revealed that it is required for maintenance of normal endoplasmic reticulum shape. PMID:27786289
5. Nogo-B is expressed aberrantly in HCCs and plays an oncogenic role. These findings support that Nogo-B may be a novel anti-HCC therapeutic target. PMID:28628795
6. observations suggest that Rtn4A counteracts the Nrdp1-mediated degradation of ErbB3 by sequestering the ubiquitin ligase into ER tubules. PMID:27353365
7. NOGO-A/B may be a negative prognostic factor of malignant melanoma. PMID:27354599
8. LILRA3 significantly reversed Nogo-66-mediated inhibition of neurite outgrowth and promoted synapse formation in primary cortical neurons through regulation of the ERK/MEK pathway. PMID:26826187
9. Nogo-B expression is down-regulated in intrahepatic cholangiocarcinoma, the implication of which, however, remains to be investigated. PMID:26656426
10. Data show that the mean peak serum neuroglobin and Nogo-A concentrations were both significantly higher in patients with an unfavorable outcome at 6 months after traumatic brain injury (TBI). PMID:26472601
11. RTN4-C knockdown blocks cell cycle progression and cell growth in colorectal cancer cell lines. PMID:25847052
12. Epithelial RTN-4B/NOGO-B was downregulated in human and experimental inflammatory bowel disease PMID:25907690
13. The Nogo-B-PirB axis controls macrophage-mediated vascular remodeling. PMID:24278366
14. a novel mechanism that functionally couples cAMP signaling with the proteolytic turnover of NOGO-A, positively impacting on neurite outgrowth in mammalian brain. PMID:25331889
15. The RTN4 del allele could significantly increase NSCLC risk. PMID:25040983
16. Identify Nogo-C as a tumor suppressor gene in hepatocellular carcinoma and B-raf as a novel interacting protein. PMID:24966913
17. the present study found that Nogo-A depletion was capable of inhibiting HCC SMMC-7721 cell proliferation by promoting G2/M cell cycle arrest and apoptosis. PMID:24626842
18. The expression of Nogo-B, in arterial intima, is impeded in the early stages of atherosclerosis. Macrophage infiltration is not accompanied by Nogo-B expression in atherosclerotic arteries. PMID:24372562
19. Nogo-A/B expression decreased with increasing squamous cell carcinoma malignancy grade (p=0.026). PMID:25075030
20. Neither migration speed, nor cell proliferation, or layer area sizes were influenced by Nogo-A deletion, hence suggesting another role for early postnatal Nogo-A expression in the premigratory zone of the external granule layer. PMID:24401759
21. knockdown of NgR enhanced invasion and adhesion but increased cell apoptosis in C6 cells, suggesting that Nogo-66/NgR might have complex effects on glioma cells. PMID:23982337
22. Studied premenopausal women with uterine leiomyoma. No significant association was observed between the TATC in/del polymorphism and UL risk, but increased UL risk was associated with CAA in/del polymorphism in the recessive and codominant model. PMID:23479081
23. Overexpression of Nogo-B promotes the epithelial-mesenchymal transition in cervical cancer via Fibulin-5. PMID:23042479
24. The absence of Nogo-B enhances apoptosis of hepatic stellate cells in experimental cirrhosis. PMID:23313137
25. The results demonstrate a significant change in the expression of Nogo-A during the development of the human brain PMID:23146900
26. CAA and TATC insertion/deletion polymorphisms of RNT4 gene may not be a useful marker to predict the susceptibility of ASD in Chinese Han population PMID:22313113
27. genetic variation in RTN4 3'-UTR contributes to the susceptibility to CSCC PMID:22320844
28. The presence of Nogo-A in diseased human muscle biopsies is not limited to ALS, therefore it cannot be the standard for ALS diagnosis. PMID:21503119
29. Nogo-A is a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion PMID:21835431
30. Nogo receptor 3, a paralog of NgR1,functions as a NgR1 co-receptor for Nogo-66. PMID:22133682
31. The data identify, for the first time, an effect of Nogo B in the brain and specifically show that its expression is increased in conditions where synaptic plasticity is compromised. PMID:21111015
32. Data showd that Nogo-B, a regulator of ER structure, was induced by hypoxia in pulonary artery smooht muscle cells but not the systemic vasculature through activation of the ER stress-sensitive transcription factor ATF6. PMID:21697531
33. A multi-domain fragment of Nogo-A protein is a potent inhibitor of cortical axon regeneration via Nogo receptor 1. PMID:21454605
34. No significant differences in 3'UTR TATC and CAA insertion/deletion polymorphism genotype and allele frequencies were observed between the ventricular septal defect patients and controls. PMID:21166502
35. Nogo-A is highly expressed in oligodendroglial tumors; however, it does not serve as a definite marker specific for oligodendroglial tumors PMID:20487307
36. Endogenous Nogo-B, which may exert its effects through ARPC 2/3 and MYL-9, is necessary for the migration and contraction of airway smooth muscle cells. PMID:21251247
37. Using leukocytes and endothelial cells, we show mechanistically that the silencing of Nogo-B with siRNA impairs the transmigration of neutrophils and reduces ICAM-1-stimulated phosphorylation of VE-cadherin. PMID:21183689
38. These results suggest a role for neuronal Nogo-A in maintaining a spine phenotype in neocortical pyramidal cells PMID:20938157
39. Nogo-B may regulate macrophage recruitment after unilateral ureteral obstruction, although it does not greatly affect the degree of tissue injury or fibrosis in this model. PMID:20971739
40. Reticulons, the only molecular so far to participate in all three apoptosis signaling pathways, may be a novel player in the progress of atherosclerosis. PMID:20717916
41. Epithelial reticulon 4B (Nogo-B) is an endogenous regulator of Th2-driven lung inflammation. PMID:20975041
42. Fibulin-5, a secreted extracellular matrix protein, was identified as a binding partner of Nogo-B. PMID:20599731
43. verified the molecular interaction of Nogo-A with 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP), which could act as a conformational stabilizer for the intrinsically unstructured large segment of Amino-Nogo PMID:19508346
44. identified Akt1 as a new signaling component of the amino-Nogo pathway. Akt1 phosphorylation is decreased by amino-Nogo. PMID:20018888
45. An RTN4-C mutant lacking the C-terminal domain bound to BACE1 comparably to wild-type RTN4-C & reduced Abeta40 & Abeta42 secretion by cells expressing Swedish mutant APP. PMID:19405102
46. The alteration in Nogo gene expression in muscle biopsy represents a potential diagnostic tool for the early stages of amyotrophic lateral sclerosis. PMID:12270696
47. Elevated expression of Nogo mRNA in schizophrenia was confirmed by RT-PCR. Nogo mRNA was found to contain a CAA insert polymorphism in the 3'-untranslated region. PMID:12425946
48. results describe the regulation of nogo expression through its promoter region PMID:12488097
49. ASY may be multi-functional, regulating apoptosis, tumor development, and neuronal regeneration [review] PMID:12510146
50. ER stress of highly overexpressed Nogo-B may lead to aversive cellular reactions under particular conditions. Our data do not support a function of Nogo-B as a physiological pro-apoptotic protein in certain types of cancer. PMID:12618765

Show More

Hide All

HGNC: 14085

UNIGENE: Hs.637850

KEGG: hsa:57142

STRING: 9606.ENSP00000337838

OMIM: 604475